SCHEMBL3460675

SCHEMBL3460675

Cc1cc(NC(=O)Nc2ccccc2C)ccc1N

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDX3X O00571 3/20 0.69
▸ RAB9A P51151 8/20 0.60
▸ NPC1 O15118 7/20 0.60
▸ MAPT P10636 5/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ HTT P42858 2/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ NFKB2 Q00653 1/20 0.57
▸ RELA Q04206 1/20 0.57
▸ IMPDH2 P12268 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ POLB P06746 2/20 0.54
▸ PDGFRB P09619 1/20 0.50
▸ KDR P35968 1/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3460205 0.86 SMN1; SMN2 (0.57) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL3460449 0.83 DDX3X (0.70) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL11895852 0.82 DDX3X (0.66) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL1659299 0.82 DDX3X (1.00) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL11918074 0.82 DDX3X (1.00) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL1657638 0.82 DDX3X (1.00) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL28250804 0.80 POLB (0.64) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL1275926 0.80 RAB9A (0.75) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL17084259 0.80 RAB9A (0.67) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL21247829 0.79 ALDH1A1 (0.50) DDX3XRAB9ANPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 — — US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 — — US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 — — US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 — — WO disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B DDX3X 3725/4885RAB9A 2294/4885NPC1 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback